First AD

Second AD

Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

Video content above is prompted by the following:

Can you discuss disease control with abrocitinib or upadacitinib in patients previously treated with dupilumab?

When would you switch a patient to a JAK inhibitor?

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Atopic Dermatitis

INC-22-MDD0529 - /clinical/atopic-dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Advances in Oral Systemic Treatments for Management of Atopic Dermatitis

Abrocitinib and upadacitinib, both JAK inhibitors, have shown efficacy in disease control for patients previously treated with dupilumab. These agents offer an alternative mechanism of action, potentially benefiting patients who have not achieved optimal results with dupilumab. Switching to a JAK inhibitor may be considered when a patient experiences inadequate response, loss of efficacy, or adverse effects with dupilumab. The decision to switch should be individualized, taking into account the patient's disease severity, treatment history, and risk factors associated with JAK inhibitors.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.